Rina-S + Bevacizumab
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Trial Timeline
Mar 16, 2026 → Apr 1, 2030
NCT ID
NCT07225270About Rina-S + Bevacizumab
Rina-S + Bevacizumab is a phase 3 stage product being developed by Genmab for Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07225270. Target conditions include Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07225270 | Phase 3 | Recruiting |
Competing Products
20 competing products in Ovarian Cancer